Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment.
Source: GSK news - Category: Pharmaceuticals Source Type: news